Modakafusp alfa shows intratumoral immune pharmacodynamics (PD) in a subset of patients (pts) in a phase 1b study in advanced/metastatic solid tumors

被引：0
|
作者：
Saggu, Gurpanna
Markman, Janet L.
Lee, Min Young
Dunbar, Faith
Joshi, Adarsh
Wang, Shining
Collins, Sabrina
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2024-CT065
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT065
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Phase 1b trial of anti-VEGF/PDGFR vorolanib combined with immune checkpoint inhibitors in patients with advanced solid tumors
    Bagegni, Nusayba A.
    Park, Haeseong
    Kraft, Katlyn
    O-Toole, Maura
    Gao, Feng
    Waqar, Saiama N.
    Ratner, Lee
    Morgensztern, Daniel
    Devarakonda, Siddhartha
    Amin, Manik
    Baggstrom, Maria Q.
    Liang, Chris
    Selvaggi, Giovanni
    Wang-Gillam, Andrea
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2022, 89 (04) : 487 - 497
  • [42] Pharmacokinetic (PK) and pharmacodynamic (PD) findings from a phase 1b study of ATR inhibitor tuvusertib + anti-PD-L1 avelumab in patients with advanced unresectable solid tumors
    Tolcher, Anthony W.
    Siu, Lillian L.
    Cabanas, Elena Garralda
    Boni, Valentina
    Garcia, Enrique Sanz
    Fuentes-Antras, Jesus
    Saavedra, Omar
    Coenen-Stass, Anna
    Locatelli, Giuseppe
    Vagge, Deepthi S.
    Gunhan, Burak Kursad
    Pennock, Gregory K.
    Mukker, Jatinder Kaur
    Gounaris, Ioannis
    Yap, Timothy A.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [43] Phase 1/1b trial of fruquintinib in patients with advanced solid tumors: Preliminary results of the dose expansion cohorts in refractory metastatic colorectal cancer
    Dasari, Arvind
    Hubbard, Joleen M.
    Eng, Cathy
    Yeckes-Rodin, Heather
    Ukrainskyj, Stacey M.
    Yang, Zhao
    Schelman, William R.
    Kania, Marek K.
    Bekaii-Saab, Tanios S.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [44] A phase 1 study of the PI3K/mTOR inhibitor PQR309 evaluating safety, pharmacokinetics (PK) and pharmacodynamics (PD) in patients (pts) with advanced solid tumors.
    Adjei, Alex A.
    Dy, Grace K.
    Zhao, Yujie
    Ma, Wen Wee
    Opyrchal, Mateusz
    Bakhribah, Hatoon
    Jacob, Sandra M.
    O'Hara, Corrie
    Dozier, Askia
    Cmiljanovic, Natasa
    Todaro, Barbara
    Brady, William E.
    Schmitz, Debora
    Dimitrijevic, Sasa
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [45] Immune modulation in solid tumors: a phase 1b study of RO6870810 (BET inhibitor) and atezolizumab (PD-L1 inhibitor)
    Marbach, Daniel
    Brouer-Visser, Jurriaan
    Brennan, Laura
    Wilson, Sabine
    Davydov, Iakov I.
    Staedler, Nicolas
    Duarte, Jose
    Quetglas, Iris Martinez
    Nueesch, Eveline
    Canamero, Marta
    Chesne, Evelyne
    Au-Yeung, George
    Hamilton, Erika
    Lheureux, Stephanie
    Richardson, Debra L.
    Spanggaard, Iben
    Gomes, Bruno
    Franjkovic, Izolda
    Demario, Mark
    Kornacker, Martin
    Lechner, Katharina
    BMC CANCER, 2025, 25 (01)
  • [46] A phase 1/1b dose escalation study of iniparib as a single agent and in combination with gemcitabine/carboplatin in patients with advanced solid tumors
    Mita, Monica
    Baffa, Raffaele
    Charpentier, Eric
    Lockhart, Craig A.
    Morris, John C.
    Rixe, Olivier
    Sarantopoulos, John
    Ramanathan, Ramesh
    MOLECULAR CANCER THERAPEUTICS, 2013, 12 (11)
  • [47] A phase 1b study of the safety, pharmacokinetics, and preliminary antitumor activity of citarinostat (ACY-241) in combination with paclitaxel (Pac) in patients (pts) with advanced solid tumors (AST).
    Gordon, Michael S.
    Shapiro, Geoffrey
    Sarantopoulos, John
    Juric, Dejan
    Lu, Brian
    Chen, Peng
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [48] ARRY-382 in Combination with Pembrolizumab in Patients with Advanced Solid Tumors: Results from a Phase 1b/2 Study
    Johnson, Melissa
    Dudek, Arkadiusz Z.
    Sukari, Ammar
    Call, Justin
    Kunk, Paul R.
    Lewis, Karl
    Gainor, Justin F.
    Sarantopoulos, John
    Lee, Patrice
    Golden, Adele
    Harney, Allison
    Rothenberg, S. Michael
    Zhang, Yuanyuan
    Goldman, Jonathan W.
    CLINICAL CANCER RESEARCH, 2022, 28 (12) : 2517 - 2526
  • [49] Toca 6: A phase 1b study of Toca 511 and Toca FC in patients with advanced solid tumors or lymphoma.
    Merchan, Jaime R.
    Ahnert, Jordi Rodon
    Falchook, Gerald
    Ostertag, Derek
    Tejera, Dalissa
    Gruber, Harry E.
    Jolly, Douglas J.
    Shorr, Jolene
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [50] A phase I study of oral darinaparsin in patients (pts) with advanced solid tumors (AST).
    Camacho, Luis H.
    Senzer, Neil N.
    Harb, Wael A.
    Barrett, John A.
    Korth, Christopher Charles
    Astl, Dorothea
    Jac, Jaroslaw
    Youssoufian, Hagop
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345